Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients

• Prif Awduron: Hoai‐Thu Thai (Awdur), Kimiko Koiwai (Awdur), Yoshihisa Shitara (Awdur), Hirotaka Kazama (Awdur), Jean‐Baptiste Fau (Awdur), Dorothée Semiond (Awdur), Christine Veyrat‐Follet (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Wiley, 2023-12-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Abstract This study aimed to support dosing regimen selection for isatuximab as a single agent or in combination with dexamethasone for Japanese patients with relapsed/refractory multiple myeloma (RRMM). A joint model characterizing the dynamics of serum M‐protein kinetics and its association with p...